The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and its partner version questionnaire were used to assess couples' satisfaction with the use of phosphodiesterase type 5 (PDE5) inhibitors to treat erectile dysfunction (ED) over a 3-month period. Of 161 ED patients, who together with their female partners were invited to answer separate questionnaires at home, 111 patients (68.9%; mean age 61.8 (23-87) years) and female partners (mean age 52.8 (22-77) years) returned completed questionnaires. Patients reported a substantially higher treatment satisfaction score and level of satisfaction with ED treatment than their female partners (Po0.001). Patients with milder severity of ED at baseline and better erectile function after treatment were more likely to be satisfied with the outcome of the treatment. Of the different aspects of satisfaction that patients were asked about, they reported the lowest level of satisfaction about their partners' feeling about continued treatment for ED. Our study shows that more patients than their female partners are more satisfied with medical treatment for ED. To maintain long-term therapy for ED, it is important to include female partners in the assessment and management of the therapy.
INTRODUCTION
Erectile dysfunction (ED) is a prevalent condition that is defined as persistent or recurrent inability for a man to achieve penile rigidity for satisfactory sexual intercourse. 1 The Massachusetts Male Aging Study demonstrated a 52% overall prevalence of ED in men aged 40-70 years, which was age dependent, and associated with many comorbidities. 2 The impaired quality of life in men with ED can be associated with depression, loss of self-esteem, poor self-concept, fear and mental stress. 1 Moreover, ED also affects the female partners of men with ED. 3 Women in the FEMALES (Female Experience of Men's Attitudes to Life Events and Sexuality) study reported significant declines in their sexual desire, arousal, orgasm and satisfaction with sexual activity after their partners' ED, compared with these aspects of their sexual behavior before the onset of their partner's erectile difficulties. 4 More than half of female partners of men with ED have sexual dysfunction themselves. 5 Oral phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for ED. Medical-treatment-related improvement in erectile function has been associated with enhanced quality of life, increased self-esteem and a reduction in depressive symptoms in patients with ED, 6 as well as improvement in several aspects of sexual function of their untreated female partners. [7] [8] [9] In spite of these reported improvements, there is a high dropout rate among PDE5 inhibitor responders, which ranges from 57 to 31%. 10, 11 Although the reasons for the high dropout rate are diverse, female partners of men with ED are thought to have a key supportive role in the successful long-term treatment of ED. 12 Including the female partner in consultations may highlight discordant attitudes and communication problems between couples. 12 Treatment outcomes are likely to be enhanced if the objectives of treatment are oriented towards a satisfying sexual relationship rather than enhancing penile tumescence per se. 13, 14 Greater satisfaction with ED treatment might be associated with more confidence and self-esteem and better relationships in men with ED. 15 However, only a few studies have simultaneously assessed treatment satisfaction in men and their female partners after treatment with PDE5 inhibitors. 7, [16] [17] [18] [19] Given that such data are still limited, or even lacking, in oriental couples with different cultural backgrounds, we conducted an open-label, multicenter and crosssectional, observational study to assess treatment satisfaction in Taiwanese couples, when men were administered PDE5 inhibitors for ED.
PATIENTS AND METHODS Patients
This study was conducted from June 2007 to March 2009 at two medical centers in Taiwan. Patients were eligible for the study if they were 420 years of age, had taken PDE5 inhibitors for at least 3 months for ED and had a stable relationship with a female partner.
Questionnaires
Participants were given an envelope that contained two self-administered questionnaires: one for the patient and the other for his female partner, which were to be answered separately at home. The completed questionnaires were returned by mail. The protocol of this study was reviewed and approved by the Institutional Review Board at Kaohsiung Veterans General Hospital.
The questionnaire for completion by male patients with ED contained 36 items that included demographic data, marital status, a checklist of selfreported comorbidity, characteristics of administering PDE5 inhibitors, a checklist of side effects, the Sexual Health Inventory for Men (SHIM) 20 before and after treatment, and a nonvalidated Chinese version of the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS). 21 With the exception of SHIM and EDITS, which are validated questionnaires, the other questions have not been validated. Baseline erectile function was determined by recalling the erectile status before treatment. Given the cross-sectional study design, this process involved the modified version of SHIM. The questionnaire for completion by female partners of men with ED contained only a 5-item Chinese version of the EDITS Partner.
The EDITS questionnaire contained 11 questions that were scored on a 0-4-point scale, with a higher score indicating greater satisfaction. An EDITS Index was calculated by multiplying the mean score of all 11 questions by 25, resulting in a range from 0 (lowest satisfaction) to 100 (highest satisfaction). The EDITS Partner questionnaire contained five items scored on a 0-4-point scale, and its Index was calculated in the same way as that used for the EDITS questionnaire. Treatment satisfaction was defined as an EDITS Index or EDITS Partner Index score X50, and treatment dissatisfaction as an Index score o50. The severity of ED was based on the total SHIM score, with 22-25 representing no ED, 17-21 representing mild ED, 12-16 representing mild to moderate ED, [8] [9] [10] [11] representing moderate ED and o7 representing severe ED. 22 
Statistical analysis
Descriptive statistics were used for demographic variables. The w 2 test was used for the analysis of categorical data. A paired-samples t-test was conducted to compare the dependent variables. Student's t-test and the Mann-Whitney U-test were used for parametric and nonparametric variables, respectively. Spearman's rank correlation was used to measure the association between the EDITS and the EDITS Partner Index scores. Data entry was performed using Excel 2000 (Microsoft, Redmond, WA, USA). Statistical analyses were executed using SPSS version 12.0 (Chicago, IL, USA). The null hypothesis was rejected for Po0.05.
RESULTS
Of the 161 eligible participants, 146 men returned the questionnaires and 111 couples (response rate 68.9%) had data eligible for analysis ( Figure 1 ). For the 111 couples, the mean ages of the male patients and their female partners were 61.8 ± 14.8 (23-87) and 52.8 ± 12.4 (22-77) years, respectively ( Table 1 ). The participants (n ¼ 111) had a significantly (Po0.01) lower body mass index, and were significantly (Po0.05) more likely to be married than those who were not participants (n ¼ 50); there was no significant difference in other aspects between the patients (all P40.05) ( Table 1) .
Sildenafil was the most frequently used agent (69.7% of patients), followed by vardenafil (19.3% of patients) and tadalafil (11.0% of patients). The mean SHIM score at baseline was 12.4±3.9, and approximately half of the men had either moderate or severe ED. The mean SHIM score significantly improved to 19.9 ± 3.9 (Po0.001), with sexual function returning to normal in 37 patients (33.3%), and only five of the men (4.5%) having severe or moderate ED after treatment. The most frequent side effects were flushing (44.1%), dizziness (14.4%), palpitation (7.2%), nasal stuffiness (6.3%) and headache (6.3%).
Responses to the EDITS and EDITS Partner questionnaires are shown in Table 2 . Among the 11 questions in EDITS, the mean score for Question 9 (How the partner felt about the patient's continuing with the treatment by patient) was significantly lower than for the other 10 questions (ranging from Po0.001 to P ¼ 0.014) ( Table 2 ). Among the EDITS Partner questions, the mean score for Question 5 (How the partner feels about the patient's continuing to use the treatment) was the lowest, although there was no significant difference from the other four items (P40.05).
Patients who received treatment reported a higher satisfaction score (79.6 ± 15.0 vs 57.2 ± 27.0, Po0.001) and a higher satisfaction rate (95.5% vs 61.2%, Po0.001) when compared with their female partner (Table 3) . Higher baseline and post-treatment SHIM scores were associated with patients' treatment satisfaction, whereas no factor was associated with female partners' level of satisfaction with the treatment. There was no significant difference between the EDITS Partner scores of female partners of men who were satisfied with the treatment for ED and men who were dissatisfied with the treatment for ED (Figure 2) . Of the 106 patients who were satisfied with the treatment, 65 (58.5%) had female partners, who concurrently reported satisfaction with the treatment; there was a significant, albeit weak, correlation between the levels of satisfaction among patients and the satisfaction of their female partners with the effects of ED treatment (Spearman r s ¼ 0.220, P ¼ 0.020).
DISCUSSION
Oral pharmacotherapy with PDE5 inhibitor is the most popular treatment for ED 23 , and has the highest satisfaction rate among the available modalities. 18 A high treatment satisfaction rate, ranging from 62.3% to 89% as assessed by EDITS, has been reported in ED patients treated with PDE5 inhibitors in prospective clinical trials. [15] [16] [17] [18] [19] 24 The satisfaction rate in our study (95.5%) was higher than those reported previously. The discrepancy arose primarily because we adopted a cross-sectional study, in which those who had maintained treatment for at least 3 months were more likely to be satisfied.
We showed that patients with a higher SHIM score before or after the treatment had a higher satisfaction rate with PDE5 inhibitors, than those with a lower SHIM score before or after the treatment. A cross-sectional study of 3 years clinical experience with sildenafil treatment demonstrated that the response was associated with the duration and degree of severity of ED. 25 Patients who were satisfied with sexual function were on average younger and had less severe ED, a shorter history of the condition and no history of vascular disorders. 26 A recent German study has Figure 1 . Flow diagram of the study participants.
PDE5 inhibitors for erectile dysfunction S-T Huang and B-P Jiann demonstrated that men with less severe ED reported significantly higher sexual satisfaction than their counterparts with severe dysfunction, and older men (465 years) reported greater sexual satisfaction than their younger counterparts (p65 years) at each level of severity of ED. 27 When ED has been present for a long time, and a couple has undergone an extended period without intimacy and/or sexual activity, it is often more difficult for them to benefit from efficacious treatment. 28 In general, the expectations of partners, which are possibly related to intimacy and emotional closeness, are likely to be substantially different from those of the patients, who measure success on the basis of the improved quality of their erections. 29 For the partner, success might be judged more in terms of the quality of their sexual interaction and emotional connection than the quality of their partner's erections. 30 Female partners of men with ED showed less satisfaction with PDE5 inhibitor treatment of 
PDE5 inhibitors for erectile dysfunction S-T Huang and B-P Jiann
ED than their partners (61.2% vs 95.7%, Po0.001; Table 3 ). Salonia et al. 31 have also reported that the satisfaction of female partners was significantly lower than that of patients (58% vs 86%, Po0.01) in 69 couples when the patients were treated with sildenafil. Lewis et al. 16 reported that female partners of men with ED reported a satisfaction rate of 58%, which is compatible with our result (61.2%). Heiman et al. 19 have reported that the EDITS Partner Index score of 85 female partners of sildenafil-treated men was 57.7, which is also compatible with our result of 57.2 (Table 3) . Ichikawa et al. 32 reported a satisfaction rate of 66.7% when using a new questionnaire for assessing female partners' satisfaction with sildenafil treatment for ED, which they developed.
Sexual dysfunction in female partners seemed to have an important role in the difference in the level of treatment satisfaction. Female sexual dysfunction is prevalent, with a 47% frequency of female sexual difficulty reported among female employees of two hospitals in Taiwan. 33 Among female partners who were not satisfied with ED treatment, when patients were treated with PDE5 inhibitors, 75% reported some abnormalities in their own sexual function. 31 Female partners of men with ED reported significantly lower levels of sexual satisfaction and drive than those without ED. 34 Restoring erectile function by medical treatment does not necessarily restore a satisfying sexual relationship. Female partners' sexual function should be investigated during male patients' work-up to enhance response rate of ED treatment, and to restore a satisfying sexual relationship.
An interesting result of the present study was that the patients gave the lowest score for Question 9 (How does your partner feel about your continuing to use this treatment?) of the 11-item EDITS, whereas the female partners also gave the lowest score for Question 5 (How do you think your husband or partner feels about continuing this treatment?) of the EDITS Partner. In our study, 36 of 111 patients (32.4%) reported that their female partner was unlikely to be enthusiastic about continuation with the treatment for ED. By contrast, Gil et al. 17 have reported that 95.4% of female partners of men with ED wanted their partners to continue the treatment, when asked after sildenafil treatment for ED had been administered for at least 10 weeks in a primary care setting. That study only assessed female partners who agreed voluntarily to answer the questionnaires, although we asked each patient to invite his female partner to answer the questionnaire at home. Without the consent from female partners, patients might have concern about the latters' attitude towards the continuation of treatment.
In a follow-up study for compliance to sildenafil treatment, 14.6% of discontinuation was attributed to partners' reluctance to engage in sexual activity. 10 In a series of 101 men who had been prescribed products for home intracavernosal injections, but had not used them, 51% attributed their nonuse to their partners' refusal to co-operate with this treatment. 30 In another study, 19/73 (23%) patients who abandoned sildenafil treatment attributed this to a failure of their partner to show any sexual interest during the study period. 11 These data demonstrate that involving partners in men's assessment and treatment of ED will improve outcomes for both partners. 12, 35 There were several drawbacks to our study. This was a crosssectional study, and the baseline ED status was reported by recall. Recall bias was therefore unavoidable. Our results may not be generalizable, because our participants are confined to those who had received PDE5 inhibitors treatment for at least 3 months, and might be more satisfied with the treatment than those who dropped out from the treatment. We used nonvalidated Chinese versions of the EDITS and SHIM. We only used the EDITS to assess treatment satisfaction, which focused on the effects of medication. Dimensions of sexual pleasure and confidence were not assessed by EDITS. 36 Although the sample size was small (n ¼ 111), the power was 40.8, because only the pairedsamples t-test and w 2 test were used. Female sexual function, which may influence treatment satisfaction, was not assessed in this study. Besides, we did not obtain consent from the female partners. Female partners' concerns about resuming sexual activity were not assessed. Furthermore, it was not confirmed that the men and their female partners indeed completed the evaluations intended for them.
In conclusion, administering PDE5 inhibitors for the treatment of ED resulted in a high satisfaction rate in patients with ED and a lower satisfaction rate in their female partners. Although patients' satisfaction was correlated with the severity of ED, the satisfaction PDE5 inhibitors for erectile dysfunction S-T Huang and B-P Jiann of their female partners was not correlated with any of the factors investigated. Our data demonstrate that female partners' support has an important role in increasing the likelihood that patients will continue the treatment for ED.
